Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Cancer Res. 2019 May 6;79(13):3185–3191. doi: 10.1158/0008-5472.CAN-19-0542

Figure. 4: HMGB3 positively influences ATR and CHK1 transcription.

Figure. 4:

A, Change in HMGB3 expression in A2780 and A2780/CP70 cells as a function of cisplatin treatment. B, Reduced ATR and CHK1 total mRNA levels in A2780 and CP70 cells as a function of HMGB3 depletion. Error bars indicate ± S.D. from a minimum of three experiments. P-values <0.05 indicated with * and <0.005 with ** as determined by the paired T-test. C, Chromatin immunoprecipitation assay showing the association of HMGB3 with the ATR promoters, ATR1 and ATR2, and the CHK1 promoter expressed as a percentage of input. Control indicates a region 2.5 kb upstream of the ATR1 promoter and RPL30 indicates the amplification of ribosomal protein L30 exon3 as a negative control. IgG=immunoglobulin G; H3=histone 3; HMGB3=High Mobility Group Box 3 IP. The values represented are the averages of two experiments.